Dermatopoietin®

Dermatopoietin is our trade name for human interleukin-1 alpha (IL-1a). Its INCI name is sh-Polypeptide-17. IL-1a is an epidermal cytokine produced in healthy skin by keratinocytes and in hair follicles by epithelial matrix cells, respectively, on a constitutive basis. It acts as key regulator of skin renewal and hair growth.

Dermatopoietin is the key ingredient of a patented technological platform with wide applications in skin care (cosmetics, dermatology), hair care and oral care. In combination with Hexadeltine and other active ingredients this technology allows the formulation of tailored products to promote skin and hair renewal for use in cosmetics or pharmaceutics.   

Dermatopoietin is a 159 amino acid protein. For application in cosmetic products it is produced by recombinant biotechnology in a prokaryotic expression system. Due to its size Dermatopoietin cannot penetrate skin. Contact with the first layer of living epidermal cells (keratinocytes) in the outer skin however triggers them to produce and release endogenous IL-1a, thus starting a signal cascade which propagates through the entire epidermis and eventually reaches the fibroblasts in the dermis. In the dermis IL-1a stimulates fibroblasts to produce collagen, elastin and hyaluronic acid and to release several growth and differentiation factors which act on the epidermis. In a similar way IL-1a stimulates dermal papilla cells in the hair follicles to stop excessive hair shedding and initiate the anagenic growth phase.

We call this mode of action of our products based on Dermatopoietin – triggering a signal cascade that penetrates deep into the skin without itself penetrating it – signalling cosmetics®.  

The efficacy profile of Dermatopoietin as active ingredient in cosmetic preparations has been investigated in living skin by 2-photon fluorescence microscopy, ultrasonography and cutometry. In skin the most prominent effect of Dermatopoietin is a strong stimulation of collagen deposition. This translates into a strong

  • anti-aging effect (increase of skin elasticity and skin thickness, reduction of wrinkles), and
  • anti-cellulite effect (smoothening of skin).

Applied on scalp Dermatopoietin acts (indirectly) on dermal papilla cells and thereby

  • inhibits hair shedding, and
  • promotes anagenic hair growth.

Dermatopoietin is always used in combination with Hexadeltine.

Figure: 2-photon fluorescence microscopic picture of the dermis of a 63-year old man. He treated the inside of his forearms twice daily with Dermatopoietin (right) or placebo 2s2s(left). Red: collagen, Green: elastin. Scale bar: 50 μm

Hexadeltine®

Hexadeltine is our trade name for the patented hexapeptide Tyr- D-Ala-Gly-Phe-Leu-Asp. It is a synthetically produced enkephalin analogue which has the INCI name Hexapeptide-18. As water soluble compound Hexadeltine does not penetrate skin but acts on delta opioid receptors situated on epidermal skin cells. 

The pharmacological profile of Hexadeltine supports that of Dermatopoietin: Hexadeltine potentiates the response to low and curtails the response to high concentrations of Dermatopoietin, it increases the microcirculation and it inhibits the proliferation of keratinocytes, thus preventing skin keratosis.

Hexadeltine improves the efficacy and safety profile of Dermatopoietin. United Technologies UT AG owns intellectual property rights on the compound itself, its application alone and in combination with IL-1a in cosmetics and dermatology.

Patents

United Technologies UT AG owns the following patents which protect its rights on the biotechnology platform of interleukin-1 alpha (= Dermatopoietin®) and enkephalin analogues:

1

US Patent No 7,981,409 B2

based on PCT/EP2008/054574 Publ. Nr. US 2009 0263350 A1
A method of reducing aging of skin by applying interleukin-1 alpha USA
2

Eurasian Application No 201001599

based on PCT/EP2008/054574 WO 2009/127248 A1
Cosmetic and dermatological compositions and kits containing interleukin-1 alpha Eurasia
3

Eurasian Application No 201001598

based on PCT/EP2008/055011 WO 2009/129857 A1
Hexapeptides and compositions thereof Eurasia
4

US Patent No 8,298,523 B2

based on PCT/EP2008/065152 Publ. Nr. US 2011/0189126
Compositions containing interleukin-1 alpha and peptides USA
5

European Patent Application No 08875294.4

based on PCT/EP2008/065152 WO 2010/051852 A1 Publ. Nr. 2364160
Compositions containing interleukin-1 alpha and peptides Europe
6

Eurasian Application No 201100459

based on PCT/EP2008/065152 WO 2010/051852 A1
Compositions containing interleukin-1 alpha and peptides Eurasia
7

Ukrainian Patent Application No 2011 07126

based on PCT/EP2008/065152 WO 2010/051852 A1
Compositions containing interleukin-1 alpha and peptides Ukraine
8

Japanese Patent Application No 2011-535013

based on PCT/EP2008/065152 WO 2010/051852 A1
Compositions containing interleukin-1 alpha and peptides Japan
9

Korean Patent Application No 2011-7012572

based on PCT/EP2008/065152 WO 2010/051852 A1 Divisional Application No. 2014-7008245 Published 30 May 2014 Publ. No.: 2014-66209
Cosmetic compositions containing interleukin-1 alpha and peptide Korea
10

Mexican Patent Application No MX/a/2011/009572

based on PCT/EP2009/001957
Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof Mexico
11

Chinese Patent Application No 2009801615797

based on PCT/EP2009/062639 Publ. No. CN 102573788 A
Oral care compositions containing human recombinant Interleukin-1 alpha China
12

Japanese Patent Application 2012-531243

, published on 21 Feb 2013, based on PCT/EP2009/062639
Oral care compositions containing human recombinant interleukin-1 alpha Japan
13

Korean Patent Application No 2012-7008138

based on PCT/EP2009/062639 Publ. No 2012-0081593
Oral care compositions containing human recombinant interleukin-1 alpha Korea
14

Eurasian Patent Application No 2012200196

based on PCT/EP2009/062639 WO 2011/038754 A1
Oral care compositions containing human recombinant interleukin-1 alpha Eurasia
15

Ukrainian Patent Application No 2012 05107

based on PCT/EP2009/062639 WO 2011/038754 A1
Oral care compositions containing human recombinant interleukin-1 alpha Ukraine
16

US Patent 8,603,456 B2

Application No US 13/500,358 Publ. No. US-2012-0195853-A1 based on PCT/EP2009/063078 WO 2011/042056 A1
Method of treating hair loss with compositions containing interleukin-1 alpha USA
17

Eurasian Patent Application No 201200353

based on PCT/EP2009/063078 WO 2011/042056 A1
Cosmetic method for treatment of skin and hair with cosmetic compositions containing interleukin-1 Eurasia
18

Taiwanese Patent Application No 099134009

based on PCT/EP2009/063078 WO 2011/042056 A1
Use of interleukin-1 for manufacturing compositions for treating hair loss Taiwan

Literature